Log in
NASDAQ:OBLN

Obalon Therapeutics Stock Forecast, Price & News

$0.88
+0.03 (+3.53 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.86
Now: $0.88
$0.90
50-Day Range
$0.82
MA: $0.90
$1.00
52-Week Range
$0.62
Now: $0.88
$2.14
Volume75,864 shs
Average Volume345,702 shs
Market Capitalization$6.84 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.91
Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallow able capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. As of February 27, 2020, it had three company-managed retail treatment centers in California. Obalon Therapeutics, Inc. was founded in 2008 and is headquartered in Carlsbad, California.
Read More
Obalon Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.61 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OBLN
CUSIPN/A
Phone844-362-2566
Employees34

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.28 million
Book Value$2.06 per share

Profitability

Net Income$-23,680,000.00
Net Margins-694.12%

Miscellaneous

Market Cap$6.84 million
Next Earnings Date2/25/2021 (Estimated)
OptionableOptionable
$0.88
+0.03 (+3.53 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OBLN News and Ratings via Email

Sign-up to receive the latest news and ratings for OBLN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Obalon Therapeutics (NASDAQ:OBLN) Frequently Asked Questions

How has Obalon Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Obalon Therapeutics' stock was trading at $1.04 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, OBLN shares have decreased by 15.4% and is now trading at $0.88.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Obalon Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obalon Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Obalon Therapeutics
.

What stocks does MarketBeat like better than Obalon Therapeutics?

Wall Street analysts have given Obalon Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Obalon Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Obalon Therapeutics' next earnings date?

Obalon Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Obalon Therapeutics
.

How were Obalon Therapeutics' earnings last quarter?

Obalon Therapeutics, Inc. (NASDAQ:OBLN) issued its quarterly earnings data on Friday, November, 6th. The company reported ($0.20) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.07) by $0.13. The company earned $0.04 million during the quarter. Obalon Therapeutics had a negative return on equity of 133.43% and a negative net margin of 694.12%.
View Obalon Therapeutics' earnings history
.

When did Obalon Therapeutics' stock split? How did Obalon Therapeutics' stock split work?

Obalon Therapeutics's stock reverse split on the morning of Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 24th 2019. An investor that had 100 shares of Obalon Therapeutics stock prior to the reverse split would have 10 shares after the split.

Who are some of Obalon Therapeutics' key competitors?

What other stocks do shareholders of Obalon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Obalon Therapeutics investors own include Inovio Pharmaceuticals (INO), Nabriva Therapeutics (NBRV), OPKO Health (OPK), Vaxart (VXRT), Actinium Pharmaceuticals (ATNM), Inpixon (INPX), Co-Diagnostics (CODX), NIO (NIO), Novavax (NVAX) and Onconova Therapeutics (ONTX).

Who are Obalon Therapeutics' key executives?

Obalon Therapeutics' management team includes the following people:
  • Mr. Andrew P. Rasdal, CEO, Pres & Director (Age 62, Pay $325.99k)
  • Dr. Kelly Huang Ph.D., Consultant (Age 51, Pay $800.11k)
  • Ms. Nooshin Hussainy, CFO & Sec. (Age 62)

When did Obalon Therapeutics IPO?

(OBLN) raised $75 million in an initial public offering on Thursday, October 6th 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel served as the underwriters for the IPO and BTIG was co-manager.

What is Obalon Therapeutics' stock symbol?

Obalon Therapeutics trades on the NASDAQ under the ticker symbol "OBLN."

Who are Obalon Therapeutics' major shareholders?

Obalon Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Morgan Stanley (9.01%). Company insiders that own Obalon Therapeutics stock include Amy Vandenberg, Interwest Partners X Lp, Kim P Kamdar, Nooshin Hussainy and William J Plovanic.
View institutional ownership trends for Obalon Therapeutics
.

Which institutional investors are buying Obalon Therapeutics stock?

OBLN stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley. Company insiders that have bought Obalon Therapeutics stock in the last two years include Amy Vandenberg, Interwest Partners X Lp, Kim P Kamdar, Nooshin Hussainy, and William J Plovanic.
View insider buying and selling activity for Obalon Therapeutics
.

How do I buy shares of Obalon Therapeutics?

Shares of OBLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Obalon Therapeutics' stock price today?

One share of OBLN stock can currently be purchased for approximately $0.88.

How big of a company is Obalon Therapeutics?

Obalon Therapeutics has a market capitalization of $6.84 million and generates $3.28 million in revenue each year. Obalon Therapeutics employs 34 workers across the globe.

What is Obalon Therapeutics' official website?

The official website for Obalon Therapeutics is www.obalon.com.

How can I contact Obalon Therapeutics?

Obalon Therapeutics' mailing address is 5421 Avenida Encinas Suite F, Carlsbad CA, 92008. The company can be reached via phone at 844-362-2566 or via email at [email protected]

This page was last updated on 11/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.